Article Information
History
- May 6, 2020.
Article Versions
- You are currently viewing Version 1 of this article (May 6, 2020 - 04:48).
- Version 2 (October 6, 2020 - 15:26).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Brian Cleary1,*,†,
- James A. Hay2,*,
- Brendan Blumenstiel1,
- Stacey Gabriel1,
- Aviv Regev3,4,5,† and
- Michael J. Mina1,2,6,7,†
- 1Broad Institute of MIT and Harvard, Cambridge, MA 02142 USA
- 2Centre for Communicable Disease Dynamics, Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
- 3Klarman Cell Observatory, Broad Institute of MIT and Harvard
- 4Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142 USA
- 5Howard Hughes Medical Institute, Chevy Chase, MD, USA
- 6Department of Immunology and Infectious Diseases, Harvard School of Public Health
- 7Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School
- ↵†Correspondence should be addressed to: bcleary{at}broadinstitute.org (B.C.), aregev{at}broadinstitute.org (A.R.), mmina{at}hsph.harvard.edu (M.M.)
↵* These authors contributed equally to this work
Posted May 06, 2020.
Efficient prevalence estimation and infected sample identification with group testing for SARS-CoV-2
